The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection

Hammond, Olivia; Wang, Yue; Green, Tina; Antonello, Joseph; Kuhn, Robert; Motley, Clifford; Stump, Philip; Rich, Beverly; Chirmule, Narendra; Marchese, Rocio D.

doi:10.1002/jmv.20754

Cited by 48 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different sets of serological readouts have been used to characterize the adaptive humoral immune response after varicella vaccination or infection (4,13,26,31,34,58,73,74). Comparative analysis has raised the possibility that differences in the genetic code between the vaccine strains could be responsible for disparity in vaccine-induced humoral responses (36).…”

mentioning

confidence: 99%

Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes

Tillieux

Halsey

Thomas

et al. 2008

J Virol

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes

Tillieux

Halsey

Thomas

et al. 2008

J Virol

View full text Add to dashboard Cite

show abstract

“…Subjects were monitored for injection-site and systemic clinical adverse experiences (AEs), varicella or varicella-like rash, HZ or HZ-like rash, and exposure to varicella/HZ for 28 days after each injection. VZV Ab titers from blood samples collected prevaccination and 4 weeks postvaccination were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA), a validated assay that measures immunoglobulin G antibody responses to VZV glycoproteins (12,19,24).…”

Section: Methodsmentioning

confidence: 99%

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Sutradhar

Wang

Schlienger

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

Zostavax has been shown to be efficacious in the prevention of herpes zoster and generally well tolerated in clinical trials among subjects 60 years old or older. This prespecified combined analysis from two studies compares the levels of immunogenicity and safety of Zostavax in subjects 50 to 59 years old versus those in subjects >60 years old. Varicella-zoster virus (VZV) antibody (Ab) titers were measured by glycoprotein enzyme-linked immunosorbent assay at baseline and 4 weeks postvaccination. Noninferiority was evaluated by estimated geometric mean severalfold rise (GMFR) ratio (50 to 59 years old/>60 years old) and two-sided 95% confidence interval (CI). Success was defined by a lower bound (LB) of the 95% CI of the GMFR ratio of >0.67. Acceptability of postvaccination VZV Ab was defined by an LB of the 95% CI of the GMFR of >1.4. Safety data were recorded for 28 days postvaccination by standardized vaccination report card. The estimated GMFRs from baseline to 4 weeks postvaccination were 2.6 (95% CI, 2.4, 2.9) in subjects 50 to 59 years old and 2.3 (95% CI, 2.1, 2.4) in subjects >60 years old. The estimated GMFR ratio (50 to 59 years old/>60 years old) was 1.13 (95% CI, 1.02, 1.25). No serious Zostavax-related adverse experiences were reported. After a dose of Zostavax, the GMFR of the VZV Ab response in subjects 50 to 59 years old was noninferior to that in subjects >60 years old. The VZV Ab response was acceptable in both age groups. Zostavax was generally well tolerated in both age groups.Herpes zoster (HZ), also known as shingles, is a manifestation of reactivation of varicella-zoster virus (VZV), which, as a primary infection, is responsible for chickenpox (varicella). The incidence and severity of HZ increase with age (14,26,28). In the United States, Canada, and Europe, the overall annual incidence of HZ is consistently estimated to be 3 to 4 per 1,000 population (1,7,8,11,15,18,22). The annual risk of developing HZ increases markedly around 50 years of age and rises sharply afterwards, up to 1% per year among those over 75 years of age. The lifetime risk of HZ is estimated to range from 10% to 30% in the general population, with estimates closer to 30% in recent studies (2,4,5,8,14,15), and is as high as 50% in individuals reaching 85 years of age (14,26,32).Zostavax (live zoster vaccine), a vaccine for the prevention of HZ (shingles) in individuals Ն60 years of age, has been recently licensed in the United States (3, 13, 30) and was subsequently licensed by the European Union for the prevention of HZ and HZ-related postherpetic neuralgia (PHN) in individuals Ն50 years of age (9). As demonstrated by the Shingles Prevention Study (SPS), Zostavax has been shown to reduce the incidence of HZ and PHN in adults Ն60 years of age and to lessen acute and chronic pain associated with HZ, presumably through boosting of VZV-specific immune responses (19,24). The SPS demonstrated that the VZV antibody (Ab) response correlated with vaccine effect in preventing HZ (19).Two recent studies of Zostavax enrolled su...

show abstract

“…The gpELISAs are ELISAs that use the external glycoproteins (typically gE, gB, gH) as antigens of the solid phase [219,339,371,[404][405][406][407][408][409][410][411][412] . They are sensitive enough to detect low antibody levels after vaccination, and have been used to evaluate the level of protection [407] : In one study, 95% of the vaccinated subjects had a gpELISA value of ≥ 5 U/ mL six weeks after immunisation, whereas those with values of < 5 were at three times greater risk of developing BV [413] .…”

Section: Gpelisamentioning

confidence: 99%

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Paschale

Clerici

2016

WJV

View full text Add to dashboard Cite

Varicella-zoster virus, which is responsible for varicella (chickenpox) and herpes zoster (shingles), is ubiquitous and causes an acute infection among children, especially those aged less than six years. As 90% of adults have had varicella in childhood, it is unusual to encounter an infected pregnant woman but, if the disease does appear, it can lead to complications for both the mother and fetus or newborn. The major maternal complications include pneumonia, which can lead to death if not treated. If the virus passes to the fetus, congenital varicella syndrome, neonatal varicella (particularly serious if maternal rash appears in the days immediately before or after childbirth) or herpes zoster in the early years of life may occur depending on the time of infection. A Microbiology laboratory can help in the diagnosis and management of mother-child infection at four main times: (1) when a pregnant woman has been exposed to varicella or herpes zoster, a prompt search for specific antibodies can determine whether she is susceptible to, or protected against infection; (2) when a pregnant woman develops clinical symptoms consistent with varicella, the diagnosis is usually clinical, but a laboratory can be crucial if the symptoms are doubtful or otherwise unclear (atypical patterns in immunocompromised subjects, patients with post-vaccination varicella, or subjects who have received immunoglobulins), or if there is a need for a differential diagnosis between varicella and other types of dermatoses with vesicle formation; (3) when a prenatal diagnosis of uterine infection is required in order to detect cases of congenital varicella syndrome after the onset of varicella in the mother; and (4) when the baby is born and it is necessary to confirm a diagnosis of varicella (and its complications), make a differential diagnosis between varicella and other diseases with similar symptoms, or confirm a causal relationship between maternal varicella and malformations in a newborn. Core tip: Although varicella during pregnancy is infrequent and congenital varicella syndrome (CVS) is rare, every available means should be used to prevent and diagnose them. Microbiology laboratories can be crucial in these situations: Evaluating a mother's immune status with sensitive and specific tests for the detection of antibodies; allowing a rapid diagnosis with molecular biology tests when a clinical manifestation may be due to different etiologies; following pregnant women with varicella for the prenatal diagnosis of CVS with close collaboration between molecular biology investigators and specialists in imaging diagnostics.De Paschale M, Clerici P. Microbiology laboratory and the management of mother-child varicella-zoster virus infection. World

show abstract

The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection

Cited by 48 publications

References 16 publications

Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes

Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Contact Info

Product

Resources

About